Home / Resource Library / Rituximab, Acalabrutinib, and Durvalumab for Primary Central Nervous System Lymphoma: A Single-arm, Phase 1b, Multi-center Study
Rituximab, Acalabrutinib, and Durvalumab for Primary Central Nervous System Lymphoma: A Single-arm, Phase 1b, Multi-center Study